On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing agreement with Dizal Pharmaceutical to develop and commercialize lung cancer drug Zegfrovy in a deal worth up to $1.5 billion.

Under the agreement announced on July 14, AstraZeneca will pay $600 million upfront to acquire global development and commercialization rights for the targeted therapy. The deal strengthens AstraZeneca's oncology portfolio and partially restores investor confidence following its stock decline of approximately 9% on July 9, when its jointly developed cardiac drug Wainua failed to meet the primary endpoint in a Phase III trial.

However, Dizal Pharmaceutical issued a notice on July 15 highlighting uncertainties surrounding the agreement's effectiveness, noting it remains subject to shareholder approval and overseas antitrust review. Separately, AstraZeneca recently entered a siRNA drug collaboration with CSPC Pharmaceutical worth up to $1.77 billion, signaling an accelerating pace of external pipeline acquisitions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)